PERRIGO Co plc Form 8-K April 27, 2016

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549	
FORM 8-K	
CURRENT REPORT	
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934	
Date of Report (Date of earliest event reported): April 24, 2016	
Perrigo Company plc (Exact name of registrant as specified in its charter)	
Commission file number 001-36353 Ireland (State or other jurisdiction of incorporation or organization)	Not Applicable (I.R.S. Employer Identification No.)
Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (Address of principal executive offices) +353 1 7094000 (Registrant's telephone number, including area code) Not Applicable	- (Zip Code)
(Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intend	ed to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Written communications pursuant to Rule 425 under the Sc (17 CFR 230.425)	
[] Soliciting material pursuant to Rule 14a-12 under the Exch. (17 CFR 240.14a-12)	ange Act
[] Pre-commencement communications pursuant to Rule 14d (17 CFR 240.14d-2(b))	-2(b) under the Exchange Act
[] Pre-commencement communications pursuant to Rule 13 (17 CFR 240.13e-4(c))	Be-4(c) under the Exchange Act

Item Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;

5.02 Compensatory Arrangements of Certain Officers.

Appointment of Chief Executive Officer

John T. Hendrickson was appointed Chief Executive Officer of Perrigo Company plc (the "Company"), effective April 24, 2016.

Mr. Hendrickson has served as President of the Perrigo Company since October 2015. He was formerly Executive Vice President, Global Operations & Supply Chain between 2007 and 2015 and has held numerous other management and operational leadership roles at Perrigo since he joined the Company in 1989, including leading the U.S. Consumer Healthcare business from 2003 to 2007. Mr. Hendrickson earned an MBA from the University of Notre Dame, a B.S. in Chemical Engineering at the University of Michigan, and a B.S. in Chemistry at Hope College.

There is no arrangement or understanding between Mr. Hendrickson and any other persons pursuant to which Mr. Hendrickson was selected as an officer. There are no family relationships between Mr. Hendrickson and any director or executive officer of the Company and no transactions involving Mr. Hendrickson that would require disclosure under Item 404(a) of Regulation S-K.

Appointment of Independent Chairman of the Board

The Board of Directors elected independent director Laurie Brlas to the role of Chairman of the Board, effective April 24, 2016.

Item 5.07. Submission of Matters to a Vote of Security Holders.

At the Company's Annual General Meeting of Shareholders held on April 26, 2016, the Company's shareholders voted on the following matters:

1. Election of eight directors of the Company:

Nominee For Against Abstain Broker Non-Votes

Laurie Brlas 110,533,7682,769,704 500,9606,658,231
Gary M. Cohen 110,692,5682,611,043 500,8426,658,210
Ellen R. Hoffing 111,998,3191,674,835 131,2896,658,220
Michael J. Jandernoa 111,386,9111,914,045 503,4906,658,217
Gerald K. Kunkle, Jr. 110,629,5502,672,597 502,2786,658,238
Herman Morris, Jr. 111,193,6042,109,020 501,7616,658,278
Donal O'Connor 113,193,490479,312 131,6356,658,226
Shlomo Yanai 100,544,44813,126,167133,8076,658,241

Ratification of the appointment of Ernst & Young LLP as the Company's independent auditor for the year ending 2. December 31, 2016 and authorization of the Board of Directors, acting through the Audit Committee, to fix the remuneration of the auditor:

For Against Abstain Broker Non-Votes

116,805,2451,244,9932,151,1670

3. Advisory vote to approve the Company's executive compensation:

For Against Abstain Broker Non-Votes

64,165,68249,558,00490,728 6,648,249

4. Authorization for the Company and/or any subsidiary of the Company to make market purchases and overseas market purchases of Company shares:

For Against Abstain Broker Non-Votes

119,681,029410,566371,0680

5. Determination of the price range for reissuance of treasury shares:

For Against Abstain Broker Non-Votes

117,119,2573,249,55893,839 0

SIGNATURE

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

(Registrant)

PERRIGO COMPANY PLC

By:/s/ Judy L. Brown

Dated: April 27, 2016

Judy L. Brown

Executive Vice President and

Chief Financial Officer

(Principal Accounting and Financial Officer)